First external validation of the FLIPI-L score in a single-center series of patients with follicular lymphoma.
FLIPI-L
follicular lymphoma
prognostic score
survival
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
pubmed:
1
12
2021
medline:
8
4
2022
entrez:
30
11
2021
Statut:
ppublish
Résumé
The FLIPI-L has recently been proposed as a novel prognostic index in follicular lymphoma (FL), combining FLIPI and the presence of lymphopenia. In our single-center validation in 381 FL patients, lymphopenia was less frequent than in the original publication and thus the distribution of risk categories was different. Although it was not able to properly predict time to first treatment, FLIPI-L performed slightly better than FLIPI alone in the prediction of response, early relapse, progression-free and overall survival, and histological transformation. This new tool or others encompassing parameters from the microenvironment might improve upon the prognostic ability of classical scores.
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
297-301Subventions
Organisme : Instituto de Salud Carlos III
ID : PI19/00887
Organisme : Instituto de Salud Carlos III
ID : PI19/00925
Organisme : Fundación Española de Hematología y Hemoterapia
ID : Becas de Investigación 2018
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H. WHO classification of tumours of haematopoietic and lymphoid tissues. WHO Classif Tumours. 2017.
Bachy E, Seymour JF, Feugier P, et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol. 2019;37:2815-2824.
Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33:2516-2522.
Rivas-Delgado A, Magnano L, Moreno-Velázquez M, et al. Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. Br J Haematol. 2019;184:753-759.
Alonso-Álvarez S, Magnano L, Alcoceba M, et al. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. Br J Haematol. 2017;178:699-708.
Mozas P, Rivero A, López-Guillermo A. Past, present and future of prognostic scores in follicular lymphoma. Blood Rev. 2021;50:100865.
Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258-1265.
de Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol. 2005;23:6358-6363.
Siddiqui M, Ristow K, Markovic SN, et al. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol. 2006;134:596-601.
Mozas P, Rivero A, Rivas-Delgado A, et al. A low lymphocyte-to-monocyte ratio is an independent predictor of poorer survival and higher risk of histological transformation in follicular lymphoma. Leuk Lymphoma. 2021;62:104-111.
Yang G, Mills M, Kim Y, et al. Enhancement of the Follicular Lymphoma International Prognostic Index (FLIPI) with lymphopenia (FLIPI-L): a predictor for overall survival and histologic transformation. Blood Cancer J. 2019;9:104.
Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. J Clin Oncol. 1997;15:1110-1117.
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32:3059-3067.
Huet S, Xerri L, Tesson B, et al. EZH2 alterations in follicular lymphoma: biological and clinical correlations. Blood Cancer J. 2017;7:e555.
Bolen CR, Mattiello F, Herold M, et al. Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma. Blood. 2021;137:2704-2707.
Huet S, Szafer-Glusman E, Xerri L, et al. Evaluation of clinicogenetic risk models for outcome of follicular lymphoma patients in the prima trial. Hematol Oncol. 2017;35:96-97.
Federico M, Caballero Barrigón MD, Marcheselli L, et al. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. Lancet Haematol 2018;5:e359-e367.